This award recognises the most innovative products on the market. All finalists were launched into the UK market after 1 January 2016. The judges will look for genuine innovation or product advancement leading to treatment for new indications, quicker or easier treatments, better treatment outcomes, enhanced patient safety, backed up by sound evidence. There will be no voting process and the winner will be decided by the judging panel.
WHAT: Clinisept+ is a unique high purity, stabilised hypochlorous skin cleansing technology – delivering not only greater protection against infection than existing skin disinfectants, but also greater levels of skin compatibility and therefore better patient outcomes.
Hypochlorous has been know about and studied for over 100 years, being widely recognised as the most effective disinfecting chemistry known to man, as it is rapidly bactericidal, fungicidal, virucidal and sporicidal. The human immune system utilises hypochlorous to fight infection however due to an inherent instability, in its natural form it has a half-life of less than 48 hours, thereby (until now) preventing the manufacture of a commercially viable version. Clinical Health Technologies, the UK based manufacturer of Clinisept+, has now succeeded in perfecting a stabilised, high purity version of this unique chemistry, which gives it a proven shelf life of two years, whilst fully retaining its multi-pathogen efficacy and skin compatibility.
WHY: The rationale for launching the product to the aesthetic market is that even the smallest penetration of the dermal layer, (such as a needling site), can allow the ingress of infection. There is a growing acknowledgement that bio-film infections, (which can present themselves months or even years after a procedure), are caused at the time of the procedure. According to Alijotas-Reig and Garcia-Gimenez in their 2008 paper, “There is now increasing concern that with the ever-increasing durability and longevity of modern filler products being present in the tissue, they now pose a higher risk of complications due to biofilm formation.” In 2014 Collier wrote: “The administration of dermal fillers can no longer be considered as a semi-sterile procedure - aseptic technique must be respected at all times”. The role of bacterial biofilms in aesthetic medicine. Collier H. - Journal of Aesthetic Nursing 2014. 3:10, 476-481
Infections in the aesthetic arena occur regularly, causing issues from increased healing times through permanent scarring to the need for corrective surgery. Best practice requires practitioners to follow proper aseptic techniques, including adopting the use of optimal skin cleansing and disinfecting products. A product which is bactericidal, fungicidal, virucidal and sporicidal and is also safe on human skin is a massive step forward in patient safety.
HOW and WHEN: Clinisept+ is manufactured in the UK by Clinical Health Technologies, it was presented to The Distributor’s Den at Aesthetic Medicine Live in February 2017, and was launched by distributor AestheticSource at FACE 2017.
The Novoxel Tixel system was developed to produce dramatic clinical results for a variety of skin treatments and conditions comparable to results achieved with fractional ablative lasers like CO2, but with significant benefits over competitive technologies both for the patients and the users. Previous systems have had considerable drawbacks in terms of the large size of the systems, low energy conversion efficiency of lasers, regulation and safety eyewear required for lasers etc. Novoxel's objective was to make a major leap forward with a brand-new technology that would deliver excellent results whilst overcoming previous drawbacks and offering significant unique benefits. Tixel was launched by AZTEC Services in the UK in January 2017 with a workshop in London.
Clinician Feedback:
Dr. Eric Bernstein, Pennsylvania, USA "I'm am extremely excited about the
new Tixel technology. The histology shows that this device provides unique responses leading to a new and different clinical response. The technology lends itself to an extremely broad range of treatment conditions. From non-ablative fractionated rejuvenation to CO2-like, ablative responses. I have not seen such range from a single device, and am extremely excited to explore
the possibilities.”
Dr. Amy Patdu, Manila, Philippines. “I can treat very close to eyes, eye lids, also above the eye balls. My patients experience low pain even without topical anesthesia. Treatments are quick and have no side effects. I see improvement in my patients after 2 months and 2 sessions. I see improvement in skin texture, a younger look, better definition of eye lids, improvement in lines and texture of the neck. I usually see wrinkle
reduction after 3 months of treatment.”
Dr. Rasya Dixit, Bangalore, India. “I find that my acne scar patients experience no down time and low pain even without topical anesthesia and see no bleeding like other fractional devices. My patients experience quick healing with no side effects. Acne scars are smoother and are less visible
after 1-2 months.
Biofibre Hair Implant is a device for automatic artificial hair implantation designed to treat hair loss conditions such as androgenic alopecia, female pattern hair loss (FPHL) as well as scars and burns on the scalp.
The 70s saw the start of many kinds of artificial hair being developed to help solve baldness, but due patient discomfort, scarring, rejection rate and risks, these fibres were banned from the hair restoration industry. All kinds of material were being implanted without the right protocols, proper training or research and the lack of medical regulation at that time played a part in artificial hair implantation becoming a taboo in hair restoration field.
10 years later, Medicap started to research and develop a biocompatible fibre that nowadays is well known as Biofibre, made from the same material we suture wounds: polyamide. This material meets all biocompatibility and safety requirements established by the international standards on medical devices. The fibres are not harmful for human body and produce a keratin plug that prevents microbial agents from penetrating. According to one of Biofibre clinical studies, the rate of rejection for this material is 3,8%
Biofibre is aesthetically identical to the natural hair: natural hair thickness is between 0.07-0.09 and Biofibre is 0.07. It's available in several lengths (15, 30 and 45 cm), colours (20 shades) and styles (straight, wavy and curly) so it can be exactly matched with the patient real hair.
Since Biofibre launch in November last year, Fusion GT introduced Biofibre stating that this technique is not a competitor for any other hair restoration technique. It is an alternative for not suitable patients or a complementary treatment to be combined with other technique for increasing hair volume.
Biofibre was awarded the Best Hair Beauty Device in 2016 Paris AMEC Trophy.
Biofibre Certifications: http://www.fusiongt.co.uk/wp-content/uploads/2017/06/Certifications.pdf
Biofibre Clinical Studies: http://www.fusiongt.co.uk/wp-content/uploads/2017/06/Clinical-studies-biofibre.pdf
The ProLon® Fasting Mimicking Diet (FMD™) is a five-day meal programme that is clinically proven to promote health and longevity. It was introduced to the UK market in May 2017. Clinical research shows that followers lose an average of 5lbs of fat and 1.2 inches of their waist circumference on each five-day cycle, and achieve noticeable improvements in skin, hair, energy, mood, brain function, and overall wellbeing.
The Fasting Mimicking Diet was created by Professor Valter Longo, the Director of the Longevity Institute at the University of Southern California, one of the leading centres for research on ageing and longevity, and the USC Diabetes and Obesity Research Institute. His world-class research is renowned for leading the field of nutrition and extending life expectancy. His research achievements were acknowledged with a Nobel Prize nomination in the field of Physiology or Medicine. Professor Longo saw the benefits of fasting, but also understood the limitations and wanted to change this by making fasting achievable. ProLon® provides the beneficial effects of fasting, without its potential dangers.
The ProLon® FMD™ works by nourishing the body with enough macro- and micronutrients to minimise the burden of fasting, while still convincing cells that it is fasting. It is a high-nourishment, low-protein, and low-carbohydrate meal plan, clinically shown to maintain normal levels of a wide range of health factors and positively affect the ageing process. Extensive research has shown that following an FMD™ for just two or three times a year boosts the immune system, and can cut the risk of heart disease, cancer, inflammation and other age-related diseases1,2. A recent clinical trial shows how an FMD™ can trigger pancreatic beta cell regeneration to reverse diabetes3.
ProLon® is followed for only five days per month, while the individual returns to their regular diet for the remaining 25 days, which ensures there is minimal lifestyle disruption. Due to the impact fasting has on cells, the health improvements achieved from fasting continue for up to three months after the person has returned to their regular diet1.
ProLon® is a plant-based, gluten- and lactose-free meal programme that is filled with a scientifically determined caloric and nutritional content that allows the body to thrive, while maintaining the cells in a state of fasting. Participants not only experience the benefits of fasting, but also benefit from eating clean and nutrient-rich foods that contribute to improved health.
The new 3Dose™ Unit Dose Injector is a disposable BoNT injector with a clicker system that delivers feedback when an exact unit is injected. The clicker system has 3 different settings that allow injection of half, single and multiple units. 3DOSE ensures a more accurate, consistent and easier method of injecting toxin.
The two critical variables during toxin injections are the amount of toxin injected and the anatomical place where the toxin is being injected. Regular syringes were never designed for BoNT injections and are subject to significant tolerance in accuracy. This is being exuberated during small volume injections where errors increase cumulatively during a procedure. BoNT unit volumes are difficult to administer accurately and consistently. This affects the overall result of the procedure, thus justifying a new method for accurate injections.
